-
2022-502404-73-00
4
2024-06-03
Pancreatic ductal adenocarcinoma
-
2023-508613-17-00
5
2024-05-29
Neoplasms, Head and Neck
-
2023-508808-38-00
1
2024-05-29
Solid tumors
-
2023-507632-20-00
5
2024-05-01
Multiple Myeloma
-
2023-505602-42-00
4
2024-04-30
Spinal Muscular Atrophy (SMA)
-
2023-505660-11-00
5
2024-04-24
Cholangiocarcinoma (LTT, 26.0)
-
2023-504198-19-00
5
2024-04-18
Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
-
2022-500031-37-00
5
2024-04-08
stage IA/IIA Hodgkin lymphoma
-
2022-502272-23-00
4
2024-04-08
Locally advanced unresectable or metastatic androgen receptor positive
-
2023-505871-63-00
5
2024-04-08
ER+, HER2- metastatic breast cancer following endocrine and CDK 4/6 in
-
2023-504923-20-00
5
2024-04-04
Stage II, IIIA, IIIB (N2) Non-small Cell Lung Cancer
-
2023-504031-41-00
5
2024-03-25
ER+/HER2- Early Breast Cancer
-
2023-505251-43-00
5
2024-02-28
Primary Biliary Cholangitis
-
2023-503708-10-00
5
2024-02-20
Locally advanced or metastatic breast cancer
-
2023-506703-26-00
5
2024-02-07
locally advanced rectal cancer
-
2023-505028-74-00
5
2024-01-29
Coronary artery disease
-
2023-506638-59-01
6
2024-01-09
Rheumatoid arthritis
-
2023-504637-42-01
6
2023-12-21
aortic valve stenosis
-
2023-503837-23-00
5
2023-12-12
Mucopolysaccharidosis Type II [MPS II]
-
2022-502154-13-00
5
2023-10-27
Patients with well to moderately differentiated neuroendocrine tumors
-
2022-502082-22-00
11
2023-09-14
prediabetes
-
2022-501831-18-00
4
2023-09-13
Patients with hematologic malignancies and undergoing allogenic hemato
-
2023-504709-35-00
1
2023-08-16
Locally advanced or metastatic solid tumors
-
2022-502703-30-00
6
2023-06-28
neuroendocrine tumours